This Biopharma Stock Is Trading 23% Higher In Pre-Market After Wrapping Up $4M Public Offering
The public offering included 1,199,448 shares of common stock and pre-funded warrants to purchase up to 2,568,110 shares of common stock.
AI Is Helping Cat Owners In Tokyo Keep Their Feline Friends Healthier: App Can Reportedly Detect Pain With More Than 95% Accuracy
Mayumi Kitakata, a Tokyo resident, uses the AI-driven app CatsMe! to monitor the health of her aging cat, reflecting the growing trend of AI in pet healthcare.
FDA Fast-Tracks Ipsen And Genfit’s New Liver Disease Treatment, Iqirvo
The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating primary biliary cholangitis (PBC). This approval, based on the drug's ability to reduce alkaline phosphatase levels, marks a significant advancement in therapies available for PBC.
EXCLUSIVE: ImmunoPrecise Antibodies’ Subsidiary Releases Software With Customizable Interface For AI-Driven Drug Discovery
ImmunoPrecise Antibodies launches BioStrand's LENSaiAPI software, enhancing AI-driven drug discovery and data integration for healthcare and pharmaceutical industries.
Apple Watch Now Directly Syncs With Dexcom’s G7 Glucose Monitor
Dexcom Inc. has enabled direct Apple Watch connectivity for its G7 glucose monitor, allowing users to access real-time glucose data without needing an iPhone.
Arcturus’ Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst
Arcturus Therapeutics shared Phase 1 and Phase 1b trial results for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis, showing FEV1 improvements and safety .
Class Action Against Abbott’s Glucerna Products Proceeds in Federal Court
WuXi AppTec employees collaborated with China's PLA on altitude sickness drugs, raising national security concerns in the U.S. Congressional committee calls for restricting biotech ties amid ongoing scrutiny.
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season
Moderna has submitted an FDA application for its 2024-2025 Spikevax formula, targeting the prevalent SARS-CoV-2 variant JN.1.
Why Is Robotic Surgery-Focused Penny Stock Asensus Surgical Trading Higher On Friday?
KARL STORZ Endoscopy-America has agreed to acquire Asensus Surgical for $0.35 per share, representing a 67% premium. This acquisition will bolster KARL STORZ's robotic surgical market presence.
Over 10,000 Lawsuits In Novo Nordisk’s Ozempic Case Assigned to New Judge
Judge Karen Marston takes over the high-profile Ozempic litigation involving over 10,000 lawsuits. Here's the latest.